KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EBITDA (2019 - 2025)

Historic EBITDA for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $388.4 million.

  • Royalty Pharma's EBITDA rose 743.21% to $388.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year increase of 2066.43%. This contributed to the annual value of $1.6 billion for FY2025, which is 2066.43% up from last year.
  • Royalty Pharma's EBITDA amounted to $388.4 million in Q4 2025, which was up 743.21% from $427.2 million recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's EBITDA peaked at $735.1 million during Q3 2024, and registered a low of -$482.7 million during Q4 2022.
  • Over the past 5 years, Royalty Pharma's median EBITDA value was $259.2 million (recorded in 2023), while the average stood at $269.9 million.
  • As far as peak fluctuations go, Royalty Pharma's EBITDA plummeted by 41460.33% in 2022, and later skyrocketed by 82407.89% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's EBITDA stood at $153.4 million in 2021, then plummeted by 414.6% to -$482.7 million in 2022, then surged by 226.98% to $612.9 million in 2023, then plummeted by 41.02% to $361.5 million in 2024, then grew by 7.43% to $388.4 million in 2025.
  • Its EBITDA was $388.4 million in Q4 2025, compared to $427.2 million in Q3 2025 and $209.8 million in Q2 2025.